Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder

Neuropsychopharmacology

Volumn 22, Issue 3, 2000, Pages 251-256

  Ströhle, Andreas ^a   Holsboer, Florian ^a   Rupprecht, Rainer ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

ACTH; Cholecystokinin tetrapeptide (CCK 4); Cortisol; HPA system; Panic attacks; Panic disorder

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; TETRAGASTRIN;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MALE; MENTAL DISEASE; PANIC; PRIORITY JOURNAL; STRESS;

ADRENOCORTICOTROPIC HORMONE; ADULT; FEMALE; HUMANS; HYDROCORTISONE; MALE; PANIC; PANIC DISORDER; TETRAGASTRIN;

EID: 0343852155     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00115-3     Document Type: Article

References (46)

1. Abelson J.L., Nesse R.M., Vinik A. Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry. 29:1991;1220-1223.
2. Abelson J.L., Nesse R.M., Vinik A.I. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry. 36:1994;84-96.
3. Abelson J.L., Curtis G.C., Nesse R., Fantone R., Pyke R.E., Bammert-Adams J. The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam. Biol Psychiatry. 37:1995;56-59.
4. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The panic and agoraphobia scale. Int Clin Psychopharmacol. 10:1995;73-81.
5. Biro E., Sarnyai Z., Penke B., Szabo G., Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral response to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology. 57:1993;340-345.
6. Bradwejn J., Koszycki D. Comparison of the panicogenic effects of cholecystokinin 30-33 and carbon dioxide in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 15:1991;237-239.
7. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapetide in panic disorder. Arch Gen Psychiatry. 48:1991;603-610.
8. Bradwejn J., Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry. 151:1994;261-263.
9. Bradwejn J., Koszycki D., Couëtoux du Tertre A, Paradis M, Bourin M Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic attacks in healthy volunteers. Psychopharmacology. 114:1994;257-261.
10. Cameron O.G., Lee M.A., Curtis G.C., McCann D.S. Endocrine and physiological changes during "spontaneous" panic attacks. Psychoneuroendocrinology. 12:1987;321-331.
11. Carter D.A., Lightman S.L. A role for the area postrema in mediating cholecystokinin-stimulated oxytocin secretion. Brain Res. 435:1987;327-330.
12. Coplan J.D., Klein D.F. Pharmacological probes in panic disorder. Westenberg H.G.M., Den Boer J.A., Murphy D.L. Advances in the Neurobiology of Anxiety Disorders. 1996;173-196 Wiley, Chichester.
13. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings Arch Gen Psychiatry. 46:1989;511-517.
14. Dillon D.J., Gorman J.M., Liebowitz M.R., Fyer A.J., Klein D.F. Measurement of lactate-induced panic and anxiety. Psychiatry Res. 1987; 20:1987;97-105.
15. Dunn A.J., Berridge C.W. Physiological and behavioral response to corticotropin-releasing factor administration. Is CRF a mediator of anxiety or stress response? Brain Res Rev. 15:1990;71-100.
16. Gorman J.M., Liebowitz M.R., Fyer A.J., Stein J. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry. 146:1989;148-161.
17. Guttmacher L.B., Murphy D.L., Insel T.R. Pharmacologic models of anxiety. Compr Psychiatry. 24:1983;312-326.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 32:1959;50-55.
20. Hayden-Hixson D.M., Nemeroff C.B. Role(s) of neuropeptides in responding and adaption to stress. A focus on corticotropin-releasing factor and opioid peptides Stanford S.C., Salmon P. Stress. From Synapse to Syndrome:1993;355-391 Academic Press, London.
21. Heit S., Owens M.J., Plotsky P., Nemeroff C.B. Corticotropin-releasing factor, stress, and depression. Neuroscientist. 3:1997;186-194.
22. Holsboer F., von Bardeleben U., Buller R., Heuser I., Steiger A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl. 16:1987;80-88.
23. Holsboer F., Spengler D., Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res. 93:1992;385-417.
24. Kamilaris T.C., Johnson E.O., Calogero A.E., Kalogeras K.T., Bernardini R., Chousos G.P., Gold P.W. Cholecystokinin-octapeptide stimulates hypothalamic-pituitary-adrenal function in rats. Role of corticotropin-releasing hormone Endocrinology. 130:1992;1764-1774.
25. Kellner M., Wiedemann K., Holsboer F. ANF inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci. 50:1992;1835-1842.
26. Kellner M., Herzog L., Yassouridis A., Holsboer F., Wiedemann K. A possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry. 152:1995;1365-1367.
27. Kellner M., Yassouridis A., Jahn H., Wiedemann K. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetratpeptide in patients with panic disorder. Psychopharmacology. 133:1997;55-61.
28. Koszycki D., Zabarcko R.M., Le Melledo J.-M., Young S., Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry. 40:1996;648-655.
29. Koszycki D., Zacharko R.M., Le Melledo J.-M., Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers. A comparison of panickers and nonpanickers Depression Anxiety. 8:1998;1-7.
30. B antagonist in panic disorder. Biol Psychiatry. 37:1995;462-466.
31. Levin A.P., Doran A.R., Liebowitz M.R., Fyer A.J., Gorman J.M., Klein D.F., Paul S.M. Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res. 21:1987;23-32.
32. Liebowitz M.R., Gorman J.M., Fyer A.J., Levitt M., Dillon D., Levy G., Appleby I.L., Anderson S., Palij M., Davies S.O., Klein D.F. Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry. 42:1985;709-719.
33. Owens M.J., Nemeroff C.B. The physiology and pharmacology or corticotropin-releasing factor. Pharmacol Rev. 43:1992;425-473.
34. Palmour R.M., Bradwejn J., Merani S., Meaney M.J., Koszycki D., Boulenger J.-P., Ervin F.R. Neuroendocrine correlates of CCK-4-induced anxiety and panic in normal human volunteers and in vervet monkeys. Neuropsychopharmacology. 9:1993;121S.
35. Roy-Byrne P.P., Uhde T.W., Post R.M., Gallucci W., Chousos G.P., Gold P.W. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry. 143:1986;896-899.
36. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T., Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci. 22:1997;332-340.
37. Ströhle A., Jahn H., Montkowski A., Liebsch G., Boll E., Landgraf R., Holsboer F., Wiedemann K. Central and peripheral administration of atriopeptin is anxiolytic in rats. Neuroendocrinology. 65:1997;210-215.
38. Ströhle A., Kellner M., Holsboer F., Wiedemann K. Atrial natriuretic hormone decreases endocrine response to a combined dexamethasone corticotropin-releasing hormone test. Biol Psychiatry. 43:1998;371-375. a.
39. Ströhle A., Kellner M., Yassouridis A., Holsboer F., Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry. 155:1998;610-612. b.
40. Ströhle A., Kellner M., Holsboer F., Wiedemann K. Behavioral, neuroendocrine and cardiovascular response to flumazenil. No evidence for an altered benzodiazepine receptor sensitivity in panic disorder Biol Psychiatry. 45:1999;321-326.
41. van Megen H.J.G.M., Westenberg H.G.M., Den Boer J.A., Kahn R.S. The panic inducing properties of the cholecystokinin tetrapeptide CCK-4 in patients with panic disorder. Eur Neuropsychopharmacol. 6:1996;187-194. a.
42. van Megen H.J.G.M., Westenberg H.G.M., Den Boer J.A., Kahn R.S. Cholecystokinin in panic disorder. Westenberg H.G.M., Den Boer J.A., Murphy D.L. Advances in the Neurobiology of Anxiety Disorders. 1996;197-227 Wiley, Chichester. b.
43. van Megen H.J.G.M., Westenberg H.G.M., Den Boer J.A., Slaap B., Sheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology. 129:1997;357-364.
44. Verbalis J.G., McCann M.J., McHale C.M., Stricker E.M. Oxytocin secretion in response to cholecystokinin and food. Differentiation of nausea from satiety Science. 232:1986;1417-1419.
45. Wittchen H.-U., Wunderlich U., Gruschwitz S., Zaudig M. SKID-I. Strukturiertes Klinisches Interview Für DSM-IV. 1997;Hogrefe, Göttingen.
46. Woods S.W., Charney D.S., McPherson C.A., Gradman A.H., Heninger G.R. Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry. 44:1987;365-375.